Latest news with #2024Environmental
Yahoo
19-05-2025
- Business
- Yahoo
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation
SAN FRANCISCO and SUZHOU, China, May 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the release of its "2024 Environmental, Social and Governance (ESG) Report", highlighting the Company's strategies, actions, and achievements in sustainable development across five pillars, which include "Excellent Governance", "Enjoying Good Health", "High Quality as Key", "People First" and "Embracing Ecology". Dr. Michael Yu, Founder, Chairman and CEO of Innovent, stated: "As China's leading biopharmaceutical company, Innovent consistently navigates the pulse of the times with strategic foresight, forging a closed-loop system for value creation through synergistic integration of global innovation-driven strategies and sustainable development practices. We achieved an MSCI ESG rating of AAA, as the only biotech in China and one of just three globally to receive this rating. Throughout the year of 2024, we remained committed to our mission, 'to empower patients worldwide with affordable, high-quality biopharmaceuticals,' and stayed true to our original aspiration, 'Start with Integrity, Succeed through Action.' We deeply integrated social responsibility into our business practices, actively responded to the United Nations Sustainable Development Goals (SDGs), strengthened our governance structure, improved operational efficiency, advanced high-quality innovation, promoted diversity and empowerment among employees, and strived for low-carbon development. These initiatives firmly honored our commitment to sustainable growth. We have embedded ESG principles into the fabric of our organization, which enables us to continuously create multidimensional value for shareholders, employees, patients, and society." Building Enduring Excellence through Lean Governance Robust governance is the cornerstone of sustainable business development. In 2024, Innovent further refined its ESG governance framework to ensure agility in responding to global changes while maintaining steady, compliant operations. We strengthened compliance management through continuous improvement of risk management systems and the upholding of rigorous business ethics standards. Looking ahead, we are committed to building a stable and sustainable business ecosystem in collaboration with our partners. Board Diversity: added one female Executive Director, with every Board Committee now including at least one female chair or member. Compliance, anti-corruption, and business ethics training: 100% participation among Directors and employees. Supplier business ethics: 100% of suppliers signed the "Commitment to Compliance". Official ESG website: launched in 2024, underscoring the company's firm commitment to sustainable development. ESG recognition: achieved an MSCI ESG rating of AAA, the only biotech in China and one of just three globally to receive this rating. Driving Inclusive Healthcare through Innovation Bridging geographic and economic gaps through innovative therapies remains Innovent's unwavering goal. Guided by our company strategy, "To discover new medicines through innovation and deliver them through our global platforms", Innovent has solidified its oncology leadership in China, achieved multiple groundbreaking advancements in chronic disease therapies, and expanded our global impact. Out dedication to scientific progress is grounded in a strong sense of social responsibility, which extends to improving drug accessibility and affordability for patients worldwide, rural education, volunteer activities, and broader community support initiatives. Improving drug accessibility through an innovative pipeline: 15 commercialized products have benefited 5 million patients cumulatively. 3 New Drug Applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 molecules in early clinical development. Oncology and general biomedicine have become the Company's two growth engines. 6 drugs or assets granted 13 orphan drug designations, with 2 drug candidates for rare diseases in preclinical and clinical stages. SYCUME® (teprotumumab N01 injection) was launched as China's first IGF-1R antibody for the treatment of thyroid eye disease, ending a 70-year absence of treatment options and transforming care for this rare condition. Enhancing drug affordability by supporting medical insurance coverage with 6 medicines (TYVYT®, BYVASDA®, HALPRYZA®, SULINNO®, Olverembatinib, and SINTBILO®) included in China's National Reimbursement Drug List (NRDL) and 8 medicines (Pemazyre®, Cyramza®, Retsevmo®, FUCASO®, TYVYT®, DOVBLERON®, Jaypirca® and DUPERT®) included in the Catalog of Specific Drug Reimbursements under Huimin Insurance Programs. SINTBILO® became China's first domestically developed PCSK9 inhibitor included in the NRDL. Patient assistance programs have benefited over 200,000 patients, with donated medicines valued at more than RMB 3.6 Billion. Health education and public welfare programs benefited over 240,000 patients. Ongoing efforts in supporting rural education have cumulatively benefited nearly 4,000 teachers and students. Innovent volunteer teams contributed a total of 2,754 hours of community service, reflecting our long-term commitment to social responsibility. Delivering Life-Changing Quality High-quality is a foundational principle at Innovent that underpins our mission to deliver safer, more effective therapies to patients. Patient-centricity drives our adherence to internationally recognized quality standards across the entire product lifecycle, from development and manufacturing to distribution. Even in the face of complex external environments, we actively collaborate with industry partners to elevate sector-wide benchmarks and maintain a resilient, sustainable dual-sourcing supply chain. Our responsible marketing practices further prioritize transparency and the protection of patient rights. Innovent Biologics currently operates 140,000 L of total production capacity, comprising 60,000L of antibody production capacity at Suzhou manufacturing site and 80,000L of antibody and ADC production capacity at Hangzhou manufacturing site. With an additional 90,000L of capacity in plan at the Hangzhou site, the total production capacity will reach 230,000L upon full completion. All commercially operational production facilities are 100% GMP-certified. Reached 100% batch success rate in drug substance manufacturing. Maintained 100% pass rate in audits conducted by regulatory authorities and strategic partners. Established dual-source supply chains for raw materials used in self-manufactured commercial products. Conducted 122 quality audits of suppliers; delivered capacity-building training to approximately 170 suppliers; deployed over 400 personnel to provide on-site quality supervision, guidance, and training at 10 key supplier sites. Empowering Talent and Igniting Potential A thriving talent ecosystem fuels our innovation. At Innovent, we view our employees as the foundation of long-term success and are deeply committed to cultivating a fair, inclusive, and empowering workplace. We offer diverse career development pathways and a multi-tiered professional development training system tailored to different career stages. Our comprehensive compensation and benefits framework is designed to strengthen employees' sense of belonging, while enhancing our ability to attract, retain, and develop top talent. Committed to making Innovent a learning institution, we support employees in achieving both personal and professional growth. Women represent 51% of total employees and hold 44.2% of management positions. Key talent retention rate reached 96.8%. Employee satisfaction rate exceeded 98%. The "Innovent Beginning" Campus Recruitment Program offered over 2,100 job opportunities to new graduates from nearly 20 provinces. All operational production facilities are 100% ISO 45001 occupational health and safety (OH&S) certified. Safeguarding the Green Future with a Commitment to Sustainability Green development underpins Innovent's high-quality growth strategy. We are committed to eco-friendly practices that protect natural resources and ecosystems while actively contributing to global climate action. Through comprehensive climate risk assessments, we evaluate the potential operational impacts of climate change and implement measures to reduce our business activities' climate impacts. By integrating green, low-carbon principles across all aspects of our production and operations, we continue to set clear targets that drive continuous improvement in our environmental performance and contribute to a more sustainable future. 100% of operational production facilities are certified under the ISO 14001 Environmental Management System. Successfully completed one internal and one external environmental management audit to ensure ongoing compliance and system integrity. 29% reduction in energy consumption (per unit of production) compared to the previous year. Reduced fresh water use by 22% (per unit of production) compared to the previous year. Recycled a total of 51,100 tons of water, reflecting out commitment to resource conservation. Innovent Shanghai Global R&D Center was awarded LEED Gold certification by the U.S. Green Building Council (USGBC). Innovent remains firmly committed to sustainable development and global innovation. We will continue strategically consolidating our business momentum while pursuing breakthrough innovations in science. By harmonizing business success with long-term social value, Innovent is steadily progressing toward its vision of becoming a premier global biopharmaceutical company. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2)Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content to download multimedia: SOURCE Innovent Biologics Sign in to access your portfolio
Globe and Mail
30-04-2025
- Automotive
- Globe and Mail
407 ETR details latest results and continued commitment to sustainable practices in 2024 ESG report
TORONTO , April 30, 2025 /CNW/ - 407 ETR released its 2024 Environmental, Social and Governance (ESG) Report, Future Forward, outlining the Company's progress in key areas of sustainability and responsible business practices. Marking the sixth year of reporting, the publication provides a detailed look at 407 ETR's ESG strategy and performance metrics. "At 407 ETR, ESG principles are deeply ingrained into our corporate culture and decision‑making processes," says Javier Tamargo , President & CEO, 407 ETR. "Our long-term success is closely tied to creating value for our stakeholders, including the vibrant communities we serve in the GTA, especially in times of uncertainty." In 2024, 407 ETR updated its materiality assessment to validate and update current material ESG factors, which helps guide the Company's ESG strategy and informs the allocation of efforts and resources. Read the full report at Fast facts Environmental priorities Reduced Scope 1 and Scope 2 GHG emissions by 19% against the 2018 baseline. On track to achieve target of 25% emissions reduction by 2030. Donated over $600,000 to support local biodiversity initiatives. On track to complete $1.8 million investment in environmental initiatives over three years (2023-2025). Planted 20,000 native trees along Highway 407 ETR and head office. Completed green fleet study to explore low emissions alternatives and fuel-optimization opportunities for company vehicles. Operational achievements Achieved a 90% customer service satisfaction rate and 82% first call resolution rate. Recognized with the 2024 Diversity, Equity and Inclusion award from the International Bridge, Tunnel and Turnpike Association for building diversity and inclusivity on and off the road. Reported 60% lower collision rate compared to alternate 400-series highways in the GTA 1. Invested $25 million in highway capital projects through third-party contractors to improve driving experience and customer safety. Invested $8 million in enforcement and policing services to help keep the highway safe. Community investments Introduced Route Relief, a new financial assistance program that helps low-income drivers access Highway 407 ETR through free travel. Invested approximately $1.7 million in GTA communities through sponsorships, donations and free travel. Donated $50,000 to support local Indigenous organizations. Invested $135,000 through Keep Moving TM by 407 ETR, helping over 3,500 GTA youth access team sports programs. Donated over $120,000 to United Way Greater Toronto through employee fundraising and corporate matching program. About 407 ETR Highway 407 ETR is an all-electronic open-access toll highway located in the Greater Toronto Area in Ontario, Canada . The highway spans 108 kilometres from Burlington in the west to Pickering in the east. 407 International Inc. is the sole shareholder of 407 ETR and is owned by:
Associated Press
30-04-2025
- Business
- Associated Press
GEON Performance Solutions Reports Reductions in Waste, Water Consumption, Electricity Usage in 2024 ESG Report
WESTLAKE, OHIO / ACCESS Newswire / April 30, 2025 / GEON® Performance Solutions, a global leader in the formulation, development and manufacture of performance polymer solutions, released its 2024 Environmental, Social and Governance (ESG) Report which illustrates advances in bringing its sustainability strategy to life for global associates, customers and 2024 ESG Performance GEON 2024 ESG Performance The ESG Report measures GEON's progress towards its three overarching sustainability goals: 1) Optimize and advance operational excellence, 2) Shape thriving communities, and 3) Collaborate and innovate across our value chain. 'Our 2024 report indicates our all-encompassing commitment to imprint a sustainability mindset into every aspect of our operations,' said GEON Chief Executive Officer Tracy Garrison. 'Sustainability is not just a goal at GEON, it is part of our ethos. I'm proud of the results outlined in our 2024 report and pleased to share progress on all the pillars.' Among the many ESG accomplishments covered in the report, a few key highlights from 2024 demonstrate how GEON: GEON began its ESG journey in 2020 when it launched GEON Vision 2025: a set of actionable, outcome-driven goals to evolve its business and maximize positive impact. 'As we work through the final year of Vision 2025, we do so with a mindset to optimize and advance operational excellence, shape thriving communities, and collaborate and innovate across our value chain,' Garrison said. View GEON's full progress in the 2024 ESG Report. For more on GEON's approach to sustainability, visit our Sustainability website. About GEON Performance Solutions GEON® Performance Solutions is a global leader in the formulation, development and manufacture of performance polymer solutions. With a portfolio of highly adaptable vinyl and polyolefin polymer technologies as well as a full-service manufacturing business, GEON combines three powerful traditions into a single, customer-focused business. GEON Performance Solutions is a leading innovator in the development of performance material solutions for a broad range of markets including appliances, building & infrastructure, electronics, medical, transportation, power & communications and more. GEON Performance Solutions has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Please visit us at to learn more. GEON Performance Solutions is a portfolio company of SK Capital Partners. About SK Capital Partners SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The Firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital's portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries. The Firm currently has approximately $9 billion in assets under management. For more information, please visit ### Contact InformationRenita Anderson Vice President, Marketing & Business Development 678-772-8953 SOURCE: GEON Performance Solutions press release
Associated Press
28-04-2025
- Business
- Associated Press
VNET Publishes 2024 Environmental, Social and Governance Report
BEIJING, April 28, 2025 /PRNewswire/ -- VNET Group, Inc. (NASDAQ: VNET) ('VNET' or the 'Company'), a leading carrier- and cloud-neutral internet data center services provider in China, today announced it has published its 2024 Environmental, Social and Governance Report (the '2024 ESG Report'). This is VNET's fifth ESG report, highlighting the Company's 2024 efforts and achievements in environmental practices, digital empowerment, ethical governance, and social responsibility. 'As an integral element of VNET's long-term strategy for sustainable growth, our 2024 ESG initiatives drove measurable advancements in our pursuit of a greener future,' Josh Sheng Chen, Founder, Executive Chairperson, and interim Chief Executive Officer of VNET. 'Upgrades to our 'SHIELD' (Society, Human, Innovation, Environment, Leadership, Development) sustainability system broadened stakeholder coverage and amplified our impact, reinforcing our position as an industry leader in sustainability. Heading into 2025, we will remain committed to integrating ESG best practices across our business, facilitating the development of China's green, digital economy while creating sustainable value for all stakeholders.' 2024 ESG Report Highlights: To view the full 2024 ESG Report, please visit the Company's Investor Relations website at or access the report directly at About VNET VNET Group, Inc. is a leading carrier- and cloud-neutral internet data center services provider in China. VNET provides hosting and related services, including IDC services, cloud services, and business VPN services to improve the reliability, security, and speed of its customers' internet infrastructure. Customers may locate their servers and equipment in VNET's data centers and connect to China's internet backbone. VNET operates in more than 30 cities throughout China, servicing a diversified and loyal base of over 7,000 hosting and related enterprise customers that span numerous industries ranging from internet companies to government entities and blue-chip enterprises to small- to mid-sized enterprises. Safe Harbor Statement This announcement contains forward-looking statements. These forward-looking statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'target,' 'believes,' 'estimates' and similar statements. Among other things, quotations from management in this announcement as well as VNET's strategic and operational plans, contain forward-looking statements. VNET may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about VNET's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: VNET's goals and strategies; VNET's liquidity conditions; VNET's expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, VNET's services; VNET's expectations regarding keeping and strengthening its relationships with customers; VNET's plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where VNET provides solutions and services. Further information regarding these and other risks is included in VNET's reports filed with, or furnished to, the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and VNET undertakes no duty to update such information, except as required under applicable law. Investor Relations Contact: Xinyuan Liu Tel: +86 10 8456 2121 Email: [email protected] View original content: SOURCE VNET Group, Inc.
Cision Canada
27-04-2025
- Business
- Cision Canada
Hikvision releases 2024 ESG report, delivering THRIVE for a better future
HANGZHOU, China, April 27, 2025 /CNW/ -- Hikvision has published its 2024 Environmental, Social and Governance (ESG) Report, marking seven consecutive years of sharing its ESG commitments and practices. Notably, the THRIVE sustainability philosophy was introduced for the first time. Guided by "Tech for Good", Hikvision outlines five focus areas — Harmony, Reliability, Integrity, Value Chain and Environment. By thoroughly reviewing the global policies, ESG rating criteria and stakeholder perspectives, Hikvision identified 3 material topics: 'Technological Innovation', 'Cybersecurity and Data Protection', and 'Response to Climate Change'. Driving social progress through innovation Hikvision has long explored innovative approaches to addressing social challenges. In urban governance, Hikvision has provided traffic management solutions across over 300 cities, optimizing traffic flow at over 53,000 intersections. In industrial digitalization, Hikvision partnered with CHN Energy to develop large-scale, real-time, and non-destructive bi-spectrum rapid coal quality analysis technology, overcoming the limitations of traditional methods. With its STAR Program for Social Good, Hikvision leverages its technologies to preserve wildlife, environment and culture. By 2024, Hikvision has partnered with over 30 NGOs. Notable efforts include enhancing fire prevention at Lanxi Bridge, an ancient wooden bridge built in 1574, and upgrading the observation system at South Africa's Kariega Game Reserve. Enhancing the reliability of cybersecurity and data protection Hikvision consistently prioritizes cybersecurity and data protection, a commitment that has been recognized by prestigious certifications, including ISO 27017, ISO 27018, DCMM, and IEC 62443-4-1, among others. Furthermore, Hikvision places a strong emphasis on skills and training. In 2024, Hikvision launched 26 cybersecurity-themed courses and conducted 171 training sessions, achieving 100% employee engagement. Hikvision is also fostering the next generation of talent by supporting the inaugural Hackathon at ISE 2025 in Barcelona. Tackling climate change with low-carbon strategies Hikvision integrates decarbonization strategies into its corporate policies, establishing a carbon-neutral business blueprint focused on low-carbon products, intelligent manufacturing, green operations, and digital transformation. Key milestones include Hikvision's Carbon Footprint Verification for 103 models and the world's first certification for Carbon Footprint of Product Process from Bureau Veritas. 16 of Hikvision's LED displays received the Green Product Mark certification issued by TÜV Rheinland, making them the first in the LED display industry to achieve this distinction. Hikvision remains committed to sustainability, laying a solid foundation for stable operations and shared value. With ongoing initiatives, we THRIVE for a better future.
